Paloma Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Paloma Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,163	Closed	-$287K	–	2355
2019 Q2	$287K	Sell	5,163 -2,507	-33%	-$131K	﹤0.01%	1325
2019 Q1	$387K	Buy	+7,670	New	+$341K	0.01%	1198
2018 Q1	–	Sell	-6,082	Closed	-$325K	–	2322
2017 Q4	$325K	Sell	6,082 -2,588	-30%	-$144K	﹤0.01%	1510
2017 Q3	$517K	Buy	8,670 +4,803	+124%	+$291K	0.01%	1513
2017 Q2	$305K	Buy	+3,867	New	+$316K	﹤0.01%	1781
2014 Q3	–	Sell	-14,363	Closed	-$206K	–	1340
2014 Q2	$206K	Buy	+14,363	New	+$164K	0.01%	954

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Paloma Partners's EGRX Position: Q3 2019 in Review

Paloma Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 5,163 shares — an estimated $287K sold.

Paloma Partners first reported a position in EGRX in Q2 2014 and held it in 6 quarters. The position peaked at $517K in Q3 2017. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Paloma Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 5,163 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $287K.
Paloma Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 6 quarters.
Paloma Partners's Eagle Pharmaceuticals, Inc. position peaked at $517K in Q3 2017.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.